Physician profile
Jin Gu
NPI 1154420727
$3,924.66
in general payments reported to CMS, 2019-2025
23 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $829 · 2021: $537 · 2022: $481 · 2023: $527 · 2024: $595 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.06 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $765.83 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $646.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $583.15 | 2019-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $491.41 | 2019-2023 | |
| Corcept Therapeutics | $450.17 | 2024-2025 | Korlym |
| Boston Scientific Corporation | $212.46 | 2020 | |
| Pfizer INC. | $124.62 | 2022-2025 | |
| Abbvie INC. | $89.36 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.02 | 2023-2024 | Synjardy, Tradjenta, Glyxambi |
| Merck Sharp & Dohme LLC | $85.67 | 2021-2024 | Belsomra, Capvaxive, Gardasil 9 |
| Amgen INC. | $69.55 | 2019-2025 | Evenity |
| Glaxosmithkline, LLC. | $59.47 | 2022-2024 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $47.25 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $44.71 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $36.07 | 2023 | Opsumit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $27.49 | 2025 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $19.77 | 2023 | Collagenase Santyl |
| Allergan, INC. | $17.00 | 2020 | |
| Astellas Pharma US INC | $16.35 | 2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $14.89 | 2019 | |
| Nevro Corp. | $13.60 | 2023 | Senza |
| Dynavax Technologies Corporation | $12.46 | 2023 | Heplisav-B |
| Sanofi Pasteur INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Gu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.